25563-04-6

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Chlorophenoxy)phenylacetic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Alzheimer's Treatment:
In the field of Alzheimer's disease research, 2-(4-Chlorophenoxy)phenylacetic acid is used as a starting material for the preparation of tri-substituted thiazoles. These thiazoles act as RAGE (Receptor for Advanced Glycation End products) antagonists, which are being investigated for their potential to slow down the progression of Alzheimer's disease by modulating the inflammatory response associated with the condition.
By following the format provided in the example, the organized description and uses of 2-(4-Chlorophenoxy)phenylacetic acid are as follows:

Upstream product

• 345308-89-6 2-[2-(4-Chloro-phenoxy)-phenyl]-1-morpholin-4-yl-ethanethione 
• 88-67-5 2-Iodobenzoic acid 
• 57486-69-8 methyl 2-(2-bromophenyl)acetate 
• 106-48-9 4-chloro-phenol 
• 2444-36-2 2'-chloro-benzeneacetic acid 
• 1037313-34-0 2-[(4-chloro-phenoxy)-phenyl]-acetic acid methyl ester 
• 25958-86-5 2-(4-chlorophenoxy)phenylacetonitrile 
• 25562-95-2 4-chloro-2'-chloromethyldiphenyl ether 
• 143-33-9 sodium cyanide 
• 6410-65-7 2-(4-chloro-phenoxy)-benzoic acid 
• 25562-90-7 2-<4-Chlorphenyloxy>-benzylalkohol 
• 1193-00-6 sodium 4-chlorophenolate 
• 58351-20-5 1-(2-(4-chlorophenoxy)phenyl)ethan-1-one 

Downstream Products

• 1035404-18-2 [2-(4-chloro-phenoxy)-phenyl]-acetyl chloride 
• 1035404-19-3 methyl-N-[2-(4-chloro-2-phenoxyphenyl)-1-oxo-ethyl]-N-methylglycinate 
• 1383781-83-6 methyl 2-[2-(4-chlorophenoxy)phenyl]-3-hydroxyacrylate 
• 1037313-34-0 2-[(4-chloro-phenoxy)-phenyl]-acetic acid methyl ester 
• 1383781-81-4 3-[2-(4-chlorophenoxy)phenyl]-4-hydroxy-1-methylpyrrolidine-2-one 
• 912356-09-3 cis-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one 
• 912356-09-3 trans-11-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one 
• 934996-79-9 5-chloro-2-methyl-2,3-dihydro-1H-dibenzo[2,3:6,7]oxepino [4,5-c]pyrrole-1-one 
• 85650-56-2 trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz<2,3:6,7>oxepino<4,5-c>pyrrolidine maleate 
• 65576-45-6 asenapine 
• 1035404-17-1 ethyl N-[2-[2-(4-chlorophenoxy)phenyl]acetyl]-N-methylglycinate 
• 1099823-68-3 ethyl 2-(2-(4-chlorophenoxy)phenyl)acetate 
• 72281-24-4 [2-(8-Chloro-dibenzo[b,f]oxepin-10-ylsulfanyl)-ethyl]-methyl-carbamic acid phenyl ester 

Relevant academic research and scientific papers

Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole

This invention provides improved processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole, asenapine. These processes allow the preparation of asenapine at industrial scale in good yields and high stereoselectivity.

PROCESS FOR THE PREPARATION OF (3ARS,12BRS)-5-CHLORO-2-METHYL-2,3,3A12B-TETRAHYDRO-1HDIBENZO[2,3:6,7] OXEPINO [4,5-C]PYRROLE MALEATE AND IT'S PHARMACEUTICAL COMPOSITION THEREOF

The present invention relates to an improved process for the preparation (3aRS,12bRS)-5-Chloro-2-menthyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino [4,5-c]pyrrole maleate represented by the compound of formula-1a and its pharmaceutical composition.(F)

ASENAPINE MALEATE

Aspects of the present application relate to a microcrystalline monoclinic form of asenapine maleate represented by structural Formula (I); processes for its preparation; and pharmaceutically acceptable dosage forms thereof.

PROCESS FOR PRODUCING TRANS-DIBENZOXENOPYRROLE COMPOUND AND INTERMEDIATE THEREFOR

The invention provides a process for production of trans-dibenzoxenopyrrole compounds, in which reduction, leaving group conversion, hydrogenation and methylation are carried out in that order. The process of the invention allows trans-dibenzoxenopyrrole compounds to be produced by a simpler procedure than conventional processes. The invention further provides novel compounds obtained as intermediates in the process, and a process for their production.

Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors

The p38 MAP kinase is a key enzyme in inflammatory diseases as it is involved in the biosynthesis of proinflammatory cytokines such as TNF-α and IL-1β. Small molecule p38 inhibitors suppress the production of these cytokines and therefore p38 is a promisi

Intermediate compounds for the prepation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole

Disclosed are novel amino acid derivatives of formula (I) and (II) processes for the preparation thereof, and their use in the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrole.

Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole

Disclosed are novel amino acid derivatives of formula (I) and (II) processes for the preparation thereof, and their use in the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrole.

Substituted (2-Phenoxyphenyl)acetic Acids with Antiinflammatory Activity. 1

The synthesis and antiinflammatory activity of a series of substituted (2-phenoxyphenyl)acetic acids are described.Initial screening in the adjuvant arthritis test showed that halogen substitution in the phenoxy ring enhanced activity considerably.Ulcerogenic potential, as measured by the minimum ulcerogenic dose (MUD), was low in almost all the acids tested. acetic acid possessed the most favorable combination of potency with low toxicity, including ulcerogenicity, and this compound is now in therapeutic use.

Affinity of 10-(4-Methylpiperazino)dibenzoxepins for Clozapine and Spiroperidol Binding Sites in Rat Brain

10-(4-Methylpiperazino)dibenzoxepins were prepared and evaluated as potential antipsychotic agents using specific clozapine diazepine> binding sites in rat forebrain that are noncholinergic and nondopaminergic in nature and from which clozapine is displaced by known antipsychotic agents. Clozapine binding in the presence of atropine represents nonmuscarinic binding, while binding in the absence of atropine represents muscarinic (cholinergic) plus nonmuscarinic binding.The relative affinity for dopamine binding sites was determined by displacement of spiroperidol from binding sites in rat caudate nuclei.Thus, clozapine, its 2-chloro isomer, its dechloro analogue, and their 5H-dibenzocycloheptene and dibenzoxepin analogues have about the same relative affinity for the nonmuscarinic clozapine binding sites.At the spiroperidol (dopaminergic) sites, both the nature of the tricyclic system and the presence of chlorine atom on the tricyclic system have a substantial effect on the binding affinity.Within each series, shift of a chlorine atom from the position distal to the piperazino group to the proximal position increases the binding affinity by a factor of about nine, but removal of the chlorine atom substantially decreases the binding affinity.Nevertheless, 10-(4-methylpiperazino)dibenzoxepin has a threefold greater affinity for the dopaminergic binding sites than does clozapine itself.

Tricyclics with analgesic and antidepressant activity: I. [[(Alkylamino)ethyl]thio]dibenzo[b,f]oxepins and 10,11-dihydro derivatives

A series of [[(alkylamino)ethyl]thio]dibenz[b,f]oxepins and their 10,11-dihydro derivatives was synthesized and subjected to broad analgesic/CNS screening. Several analogues of both types, carrying small N-substituents and frequently a nuclear fluorine fu